Mitsubishi UFJ Trust & Banking Corp Has $11.10 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

Mitsubishi UFJ Trust & Banking Corp cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 21.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 79,048 shares of the company’s stock after selling 20,978 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Neurocrine Biosciences were worth $11,097,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Dodge & Cox lifted its position in shares of Neurocrine Biosciences by 0.6% in the 2nd quarter. Dodge & Cox now owns 5,566,814 shares of the company’s stock valued at $699,693,000 after acquiring an additional 32,190 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock valued at $535,659,000 after purchasing an additional 1,590,749 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Neurocrine Biosciences by 40.5% in the second quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock valued at $189,794,000 after purchasing an additional 435,385 shares in the last quarter. Norges Bank purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at $122,278,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Neurocrine Biosciences by 1.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 789,715 shares of the company’s stock worth $99,259,000 after buying an additional 13,942 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 1,190 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the sale, the director owned 6,239 shares of the company’s stock, valued at $967,606.51. The trade was a 16.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William H. Rastetter sold 18,000 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the completion of the transaction, the director owned 40,360 shares of the company’s stock, valued at approximately $6,127,455.20. This represents a 30.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 80,266 shares of company stock valued at $11,400,517 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Stock Up 0.6%

NBIX stock opened at $134.66 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18. The company has a market cap of $13.43 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 0.70 and a beta of 0.28. The business’s 50-day simple moving average is $143.27 and its 200 day simple moving average is $140.20.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. During the same quarter in the prior year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several research analyst reports. Piper Sandler lifted their target price on Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada raised their price target on shares of Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Truist Financial cut their price objective on Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. TD Cowen lifted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, HC Wainwright raised their target price on Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $174.25.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.